Agent for treating high-risk impaired glucose tolerance
AssigneeTakeda Chemical Industries, Ltd.
InventorsHiroyuki Odaka, Ichiro Nakaoka, Yoshiharu Suzuki
Life of this patent
Estimating the term…
Abstract
The present invention discloses an α-glucosidase inhibitor for prevention of transition from high-risk IGT to diabetes mellitus, for prophylaxis of diabetes mellitus, as well as for treating high-risk IGT.
Claims9
A method of preventing transition from high-risk impaired glucose tolerance exhibiting a blood glucose level between 170 and 199 mg/dl at 2 hours in a 75 g oral glucose tolerance test to diabetes mellitus exhibiting a blood glucose level of 200 mg/dl or above at 2 hours in a 75 g oral glucose tolerance test in a mammal in need thereof, which comprises administering to said mammal an effective amount of α-glucosidase inhibitor within 60 minutes before a meal for 13 weeks or longer.
A method of treating high-risk impaired glucose tolerance exhibiting a blood glucose level between 170 and 199 mg/dl at 2 hours in a 75 g oral glucose tolerance test in a mammal in need thereof, which comprises administering to said mammal an effective amount of α-glucosidase inhibitor within 60 minutes before a meal for 13 weeks or longer and until the blood glucose level at 2 hours in a 75 g oral glucose tolerance test decreases to the level below 140 mg/dl.
Dependencies are inferred from the claim text.